Arvinas, Inc. logo

Arvinas, Inc.

NASDAQ:ARVN

Overview | Financials
Company Name Arvinas, Inc.
Symbol ARVN
Currency USD
Price 25.05
Market Cap 1,719,634,905
Dividend Yield 0%
52-week-range 13.57 - 53.08
Industry Biotechnology
Sector Healthcare
CEO Dr. John G. Houston Ph.D.
Website https://www.arvinas.com

An error occurred while fetching data.

About Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men

Related Stocks

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

1.74 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

38.11 USD

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

33.99 USD

Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

BEAM

26.3 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

2.75 USD

Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

4.02 USD

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

4.79 USD

Amicus Therapeutics, Inc. logo

Amicus Therapeutics, Inc.

FOLD

11.3 USD

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

IOVA

10.34 USD

Financials

Numbers are in millions USD

Numbers are in millions USD